By Matt Grossman


Pfizer Inc. said a Phase 3 study in which patients were administered Covid-19 vaccines and the company's Prevnar vaccine for pneumococcal disease at the same time led to positive top-line results.

In the study, responses elicited by the Prevnar vaccine for Covid-19 were similar whether or not the vaccine was given alongside a Covid-19 vaccine. The same was true for Covid-19 vaccination. The safety profiles of the shots were little changed compared with being administered separately, the company said.

Giving two vaccines at once could be a way to promote vaccine update, Pfizer said.

"As the Covid-19 vaccines and booster doses continue to be administered, we believe that healthcare providers have an opportunity to talk to their adult patients about other recommended vaccines in line with CDC guidance," the company said.

Pfizer created its Covid-19 vaccine alongside BioNTech SE.


Write to Matt Grossman at


(END) Dow Jones Newswires

January 12, 2022 07:22 ET (12:22 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2022 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 5 2021 まで 5 2022 Pfizerのチャートをもっと見るにはこちらをクリック